The Use of Splenectomy to Manage Platelet Transfusion Refractoriness due to Anti-Human Leukocyte Antibodies in Allogeneic Stem Cell Transplantation

In patients undergoing hematopoietic stem cell transplantation (HSCT), refractoriness to platelet transfusion has been associated with graft failure, delayed engraftment, early mortality and decreased overall survival. Therapeutic strategies include plasma exchange, immunoglobulins, rituximab, and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Mauro, Margherita, Camoglio, Francesco, Piccoli, Pierluigi, De Bortoli, Massimiliano, Balter, Rita, Pegoraro, Anna, Cesaro, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821215/
https://www.ncbi.nlm.nih.gov/pubmed/27114815
http://dx.doi.org/10.4081/pr.2016.6159
_version_ 1782425543146209280
author Mauro, Margherita
Camoglio, Francesco
Piccoli, Pierluigi
De Bortoli, Massimiliano
Balter, Rita
Pegoraro, Anna
Cesaro, Simone
author_facet Mauro, Margherita
Camoglio, Francesco
Piccoli, Pierluigi
De Bortoli, Massimiliano
Balter, Rita
Pegoraro, Anna
Cesaro, Simone
author_sort Mauro, Margherita
collection PubMed
description In patients undergoing hematopoietic stem cell transplantation (HSCT), refractoriness to platelet transfusion has been associated with graft failure, delayed engraftment, early mortality and decreased overall survival. Therapeutic strategies include plasma exchange, immunoglobulins, rituximab, and splenectomy. We describe here three patients with refractoriness to platelet transfusion due to anti-human leukocyte antibodies who were splenectomized before HSCT (two cases) and after HSCT (one case) due to the lack of efficacy of other therapies. Splenectomy was uneventful. All three patients achieved a full donor engraftment. We suggest that splenectomy is feasible and effective in HSCT patients to reduce the risk of graft failure or delayed engraftment.
format Online
Article
Text
id pubmed-4821215
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher PAGEPress Publications, Pavia, Italy
record_format MEDLINE/PubMed
spelling pubmed-48212152016-04-25 The Use of Splenectomy to Manage Platelet Transfusion Refractoriness due to Anti-Human Leukocyte Antibodies in Allogeneic Stem Cell Transplantation Mauro, Margherita Camoglio, Francesco Piccoli, Pierluigi De Bortoli, Massimiliano Balter, Rita Pegoraro, Anna Cesaro, Simone Pediatr Rep Case Report In patients undergoing hematopoietic stem cell transplantation (HSCT), refractoriness to platelet transfusion has been associated with graft failure, delayed engraftment, early mortality and decreased overall survival. Therapeutic strategies include plasma exchange, immunoglobulins, rituximab, and splenectomy. We describe here three patients with refractoriness to platelet transfusion due to anti-human leukocyte antibodies who were splenectomized before HSCT (two cases) and after HSCT (one case) due to the lack of efficacy of other therapies. Splenectomy was uneventful. All three patients achieved a full donor engraftment. We suggest that splenectomy is feasible and effective in HSCT patients to reduce the risk of graft failure or delayed engraftment. PAGEPress Publications, Pavia, Italy 2016-03-31 /pmc/articles/PMC4821215/ /pubmed/27114815 http://dx.doi.org/10.4081/pr.2016.6159 Text en ©Copyright M. Mauro et al. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Mauro, Margherita
Camoglio, Francesco
Piccoli, Pierluigi
De Bortoli, Massimiliano
Balter, Rita
Pegoraro, Anna
Cesaro, Simone
The Use of Splenectomy to Manage Platelet Transfusion Refractoriness due to Anti-Human Leukocyte Antibodies in Allogeneic Stem Cell Transplantation
title The Use of Splenectomy to Manage Platelet Transfusion Refractoriness due to Anti-Human Leukocyte Antibodies in Allogeneic Stem Cell Transplantation
title_full The Use of Splenectomy to Manage Platelet Transfusion Refractoriness due to Anti-Human Leukocyte Antibodies in Allogeneic Stem Cell Transplantation
title_fullStr The Use of Splenectomy to Manage Platelet Transfusion Refractoriness due to Anti-Human Leukocyte Antibodies in Allogeneic Stem Cell Transplantation
title_full_unstemmed The Use of Splenectomy to Manage Platelet Transfusion Refractoriness due to Anti-Human Leukocyte Antibodies in Allogeneic Stem Cell Transplantation
title_short The Use of Splenectomy to Manage Platelet Transfusion Refractoriness due to Anti-Human Leukocyte Antibodies in Allogeneic Stem Cell Transplantation
title_sort use of splenectomy to manage platelet transfusion refractoriness due to anti-human leukocyte antibodies in allogeneic stem cell transplantation
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821215/
https://www.ncbi.nlm.nih.gov/pubmed/27114815
http://dx.doi.org/10.4081/pr.2016.6159
work_keys_str_mv AT mauromargherita theuseofsplenectomytomanageplatelettransfusionrefractorinessduetoantihumanleukocyteantibodiesinallogeneicstemcelltransplantation
AT camogliofrancesco theuseofsplenectomytomanageplatelettransfusionrefractorinessduetoantihumanleukocyteantibodiesinallogeneicstemcelltransplantation
AT piccolipierluigi theuseofsplenectomytomanageplatelettransfusionrefractorinessduetoantihumanleukocyteantibodiesinallogeneicstemcelltransplantation
AT debortolimassimiliano theuseofsplenectomytomanageplatelettransfusionrefractorinessduetoantihumanleukocyteantibodiesinallogeneicstemcelltransplantation
AT balterrita theuseofsplenectomytomanageplatelettransfusionrefractorinessduetoantihumanleukocyteantibodiesinallogeneicstemcelltransplantation
AT pegoraroanna theuseofsplenectomytomanageplatelettransfusionrefractorinessduetoantihumanleukocyteantibodiesinallogeneicstemcelltransplantation
AT cesarosimone theuseofsplenectomytomanageplatelettransfusionrefractorinessduetoantihumanleukocyteantibodiesinallogeneicstemcelltransplantation
AT mauromargherita useofsplenectomytomanageplatelettransfusionrefractorinessduetoantihumanleukocyteantibodiesinallogeneicstemcelltransplantation
AT camogliofrancesco useofsplenectomytomanageplatelettransfusionrefractorinessduetoantihumanleukocyteantibodiesinallogeneicstemcelltransplantation
AT piccolipierluigi useofsplenectomytomanageplatelettransfusionrefractorinessduetoantihumanleukocyteantibodiesinallogeneicstemcelltransplantation
AT debortolimassimiliano useofsplenectomytomanageplatelettransfusionrefractorinessduetoantihumanleukocyteantibodiesinallogeneicstemcelltransplantation
AT balterrita useofsplenectomytomanageplatelettransfusionrefractorinessduetoantihumanleukocyteantibodiesinallogeneicstemcelltransplantation
AT pegoraroanna useofsplenectomytomanageplatelettransfusionrefractorinessduetoantihumanleukocyteantibodiesinallogeneicstemcelltransplantation
AT cesarosimone useofsplenectomytomanageplatelettransfusionrefractorinessduetoantihumanleukocyteantibodiesinallogeneicstemcelltransplantation

Ejemplares similares